|

HDP-101 Clinical Trials

2 actively recruiting trials across 1 location

No change since May 2026

Pipeline

Phase 1: 1Phase 1/2: 1

Top Sponsors

  • Heidelberg Pharma AG1
  • Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.1

Indications

  • Cancer2
  • Multiple Myeloma and Other Plasma Cell Neoplasms1
  • Plasma Cell Disorder1
  • Multiple Myeloma1

Other1 trial

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma
Phase 1

Atlanta, Georgia1 trial

Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma

Winship Cancer Institute of Emory University

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.